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THE LATENT POOL OF HIV-1-INFECTED
CELLS
The source of latent HIV-1 infection is
a long-lived pool, most likely the latently
infected memory T-cell reservoir, harbor-
ing integrated HIV-1 proviral DNA (1–4).
Well-established techniques are available
to quantify the latent pool, and it is esti-
mated that one in a million memory
T cells of an HIV-1-positive patient bears
a replication-competent integrated
provirus (5,6). The latent reservoir of
HIV-1 within resting CD4+ T cells is es-
tablished early after the acute infection,
and the initiation of highly active anti-
retroviral therapy (HAART) during this
period does not prevent its establishment
(6–8). It is an extremely stable reservoir,
having a half-life of 6–44 months, even in
treated patients who are continuously
aviremic for long periods of time
(6,9–12). With this prolonged half-life, a
complete decay of the reservoir is not ex-
pected before 70 years of HAART treat-
ment, making eradication improbable.
These time frames might be somewhat
shorter by starting HAART early during
acute infection or by intensifying
HAART, but are not sufficient as a practi-
cal method for eradication (13,14).
EARLY STUDIES ON PURGING HIV-1
FROM LATENTLY INFECTED CELLS
With the development of effective
 antiretroviral agents to prevent HIV-1
replication in vivo came the concept that
eliminating the reservoir should be
achievable without spreading the infec-
tion to new uninfected cells. After viral
expression, latently infected cells would
then be eliminated by two possible
mechanisms. First, it is possible that upon
HIV-1 expression, a cytopathic death of
the cell would follow. Second, it is also
possible that residual HIV-1–specific cy-
totoxic T cells would kill cells expressing
HIV-1 antigens. The strategy of purging
the latent pool of HIV-1-infected CD4+
T cells was initially performed using in-
terleukin (IL)-2 and other activators of
T cells such as anti-CD3 antibodies
(OKT3). However, although such agents
caused a marked activation of the T cells,
there were unacceptable toxicities and
also an irreversible decrease in the
amount of CD4+ T cells (15,16). Other
studies using IL-2 did not reduce the
pool (17,18), perhaps because of a pau-
city of cell surface receptors for IL-2 on
the resting CD4+ T cells.
In addition, integrated provirus resid-
ing within resting regulatory CD4+ T cells
(Tregs) may also have contributed to the
lack of effect. The presence of an HIV-1
reservoir within resting Tregs in patients
on prolonged HAART has been detected;
in fact, HIV-1 DNA harboring cells
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 appeared more abundant in this subset
than in non-Tregs, but with a comparable
estimated half-life (19). Because Tregs dis-
play signs of hyporesponsiveness to cell
activation (19) and may inhibit IL-2 pro-
duction (20), this cellular subset could
have added to the viral rebound despite
IL-2 treatment (21). However, the anti -
inflammatory and immunosuppressive
effect of some histone deacetylase (HDAC)
inhibitors, such as suberoylanilide hy-
droxamic acid (SAHA; generic vorinostat)
and ITF2357 (generic givinostat) (22), is
in part owing to enhancing the produc-
tion and suppressive function of Tregs by
promoting FOXP3 acetylation (23).
Therefore, it is conceivable, but yet un-
proven, that potent HDAC inhibitor
treatment may also target the latent viral
reservoir within resting Tregs.
ROLE OF HISTONE ACETYLATION IN
HIV-1 EXPRESSION
An ideal strategy for viral purging
would induce HIV-1 expression without
inducing a global T-cell activation. There-
fore, small molecules that can directly
gain access to DNA and facilitate viral
gene expression can circumvent the limi-
tations of cell surface receptor activation.
Clearly, HDAC inhibitors meet these crite-
ria. In general, HDAC inhibitors are safe,
orally active and used widely in medi-
cine. In HIV-1 latency, maintaining his-
tones in their deacetylated form by
HDACs results in densely packed chro-
matin in the nucleosome with gene ex-
pression quiescent. On the other hand,
hyperacetylation of specific lysine
residues within nucleosomal histones dis-
rupts chromatin binding and allows tran-
scriptional activation of genes. Thus,
adding HDAC inhibitors to cell lines with
integrated HIV-1 resulted in expression of
HIV-1 without any costimulation of cy-
tokines. Table 1 lists some of the reports
on HDAC inhibition in vitro from cell
lines with integrated HIV-1. The human
macrophage cell line U1, which is derived
from the U937 line, served as the model
for a latent virus in macrophages,
whereas Ach2 cells were used as the
model for integrated HIV-1 in T cells.
WHICH HDAC IS BEST FOR HIV-1
EXPRESSION?
HDACs are divided into three major
classes on the basis of their homolog in
yeast. Class I includes HDAC-1, -2, -3
and -8. Class II is comprised of HDAC-4,
-5, -6, -7, -9 and -10. HDAC-11 has prop-
erties of both class I and class II. As
shown in Figure 1, the HIV-1 5′ long ter-
minal repeat (LTR), containing the pro-
moter and enhancer elements, has bind-
ing sites for several transcription factors
and is arranged in two nucleosomes
(nuc-0 and nuc-1) (24). These nucleo-
somes are positioned in precise locations
with respect to different regulatory ele-
Table 1. Different HDAC inhibitors that have been studied in vitro and ex vivo for HIV-1
purging.
HDAC inhibitor Assay Reference
Sodium butyrate TE671/RD cells 53
TSA, TPX U1, ACH2, J49, OM10.1 54
VPA U1, ACH2, HUT-78/IIIB/LAI 55
TSA HeLa 56
VPA RCT 57
SAHA RCT 58
SAHA J89, RCT 41
SAHA, IHI U1, ACH2 59
SAHA, VPA U1, J-Lat 60
Oxamflatin, VPA, SAHA, TSA ACH2, 8E5, J-Lat 61
SAHA, VPA 24STNLESG, Hela 42
CG05, CG06 ACH2 62
ITF2357, VPA, IHI ACH2, U1 39
TSA, oxamflatin A7 63
TPX, trapoxin; TSA, trichostatin A; RCT, resting CD4+ T cells of aviremic HIV-infected donors;
IHI, investigational HDAC inhibitors.
Figure 1. HDAC suppression of HIV-1 expression in latent CD4+ T cells. (A) In the latent
state, HDAC-1, -2 and -3 are recruited to the proviral LTR by different DNA binding proteins.
Lysine residues on histones on nuc-1 are hypoacetylated and viral transcription is
blocked. (B) Upon activation of the cell by exogenous stimuli, HDACs are replaced by his-
tone acetyltransferases and nuc-1 is hyperacetylated with chromatin remodeling and
viral gene transcription. Adapted from Colin and Van Lint (64).
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ments. During latency, nuc-1 prevents
proviral transcription, since it remains in
the hypoacetylated state. Chromatin im-
munoprecipitation assays demonstrated
that HDAC-1, -2 and -3 have a role in
HIV-1 transcriptional regulation (25,26).
Thus, class 1 HDACs are recruited to the
proviral DNA, in proximity to nuc-1,
through the action of DNA binding pro-
teins. Nuclear factor (NF)-κB p50 ho-
modimer, activating enhancer binding
protein 4 (AP-4), retinoblastoma-family
protein 2 (RBF2), as well as c-Myc and
specificity protein 1 (SP-1) recruit class I
HDACs to the LTR, which in turn results
in deacetylation of local histones, com-
paction of the chromatin and prevention
of RNA polymerase II binding (25,27–31).
In vitro studies revealed that after activa-
tion by different stimuli, histone acetyl-
transferases are recruited to the promoter
region, leading to acetylation of both H3
and H4 histones. This nuc-1 disruption
eventually allows viral transcriptional
activation to occur (25,32,33).
TRIALS WITH VALPROIC ACID TO
REDUCE THE RESERVOIR OF LATENT
VIRUS
As shown in Table 1, various HDAC
inhibitors have been studied in vitro for
HIV-1 expression. However, valproic
acid (VPA), a carboxylate HDAC in-
hibitor that is prescribed for seizures and
psychiatric disorders, is the only HDAC
inhibitor that has been combined with
HAART in clinical trials. VPA was ad-
ministered to HIV-1-infected subjects at
doses used to obtain therapeutic blood
levels for seizure control while the sub-
jects were maintained throughout the
study on the HAART regimen. In the
first study by Lehrman et al. (34), enfu-
virtide was added to the HAART regi-
men of four HIV-1-positive patients.
After 4–6 wks on intensified HAART,
VPA was added to the daily regimen for
16 weeks. Plasma levels of VPA were
tested and adjusted for 40–100 μg/mL
(comparable to 0.25–0.6 mmol/L). The
frequency of resting cell infection was
measured before and after the aug-
mented therapy and showed a signifi-
cant reduction in 3 out of 4 patients.
However, no measurements were per-
formed between the addition of efuvir-
tide to the regimen and VPA. Therefore,
an isolated effect of VPA on reducing the
viral latency pool was not established.
In light of that first study, Siliciano et
al. (35) measured the size of the HIV-1 la-
tent reservoir in nine patients receiving
both HAART and VPA for at least 3
months. Levels of latently infected cells
isolated from peripheral cells were simi-
lar to those seen in patients receiving
HAART alone. To exclude the possibility
that the patients in the study had an ex-
ceptionally large latent pool, seven pa-
tients’ latent pools were measured at
least 5 months after the initial sample
was performed. There was no reduction
of the latent reservoir. In fact, in four pa-
tients, the frequencies of HIV-1 gene ex-
pression increased. In a French single-
center study, similar frequencies of CD4+
T cells with integrated viral DNA, and
CD4+ T cells carrying a replication-
 competent virus, were observed in both
patients who were treated with HAART
alone and patients who received HAART
plus VPA (36). In 2008, a prospective
study compared infection of resting
CD4+ T cells before and after the addi-
tion of VPA to the HAART regimen of 11
HIV-1-positive aviremic patients (37). In
only 4 of 11 patients, a depletion of >50%
in resting CD4+ T-cells infection was ob-
served, but this effect waned over time,
as reported in a follow-up study (38).
Plasma HIV-1 RNA concentrations were
measured also by ultrasensitive real-time
PCR to a limit of detection of 1 copy/mL
(single-copy assay). There appeared to be
an association between a significant de-
crease in the number of copies and the
absence of low-level viremia. Because
VPA alone failed to show the desirable
effect, the researchers expanded the
study and examined the effect of comb-
ing intensified antiviral therapy and the
addition of VPA to the regimen of
aviremic patients (38). Neither ralte-
gravir nor enfuvirtide, combined with
VPA and the baseline HAART, showed a
significant decrease.
These studies clearly demonstrate that
with or without intensified HAART, the
addition of VPA is of limited value in de-
creasing the reservoir of infected resting
CD4+ T cells. Nevertheless, the potential
of HDAC inhibitors to purge the virus
has not been fully exploited. VPA is a
weak and nonspecific HDAC inhibitor.
VPA does not specifically target HDAC-1
or HDAC-2, which are thought to be the
primary HDACs that prevent HIV-1 ex-
pression. Therefore, the failure to target a
specific HDAC in the trials of VPA may
account for the lack of an effect. In addi-
tion, safety and tolerability are essential
requirements for the testing of any ex-
perimental drug in patients without a
life-threatening disease. For example, we
reported that VPA significantly increases
HIV-1 expression in the latently infected
U1 monocyte/macrophage cell line but
at concentrations that would have unac-
ceptable side effects for long-term oral
dosing (39).
VORINOSTAT, GIVINOSTAT AND
BELINOSTAT
Using more selective HDAC inhibitors
has been studied in vitro and ex vivo for
inducing HIV-1 expression. Suberoy-
lanilide hydroxamic acid (SAHA; generic
vorinostat) is a relatively selective in-
hibitor for class I HDACs, that is, by in-
hibiting HDAC-1, -2, -3 and -8, but also
with some activity against class II
HDAC-6, -10 and -11 (39). However,
SAHA lacks activity against class II
HDAC-4, -5, -7 and -8. Although SAHA
is approved for the treatment of cuta-
neous T-cell lymphoma, the gastrointesti-
nal side effects and particularly the fall
in platelets render the anticancer dosing
unacceptable for long-term use in pa-
tients with HIV-1 (40). Archin et al. (41)
examined the ability of SAHA to induce
HIV-1 expression in cell lines as well as
in virus production from resting CD4+
T cells from patients treated with anti-
retroviral agents. In those studies, SAHA
induced the in-frame marker green flo-
rescence protein (GFP) mRNA from J89
cells (latently infected Jurkat cell line en-
coding the enhanced GFP as a marker for
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Tat-driven HIV LTR expression) at
nanomolar concentrations compared
with millimolar concentrations for VPA.
However, at clinically relevant concentra-
tions of SAHA (340 nmol/L), there was
no significant increase of GFP mRNA.
When SAHA was added to CD4+ T cells
in vitro at therapeutic concentrations,
there was a low level of induction of
virus outgrowth in 4 out of 5 patient
cells. Similarly, when used with other
types of latently integrated HIV-1 cell
lines, the efficacy of SAHA was no differ-
ent from that of VPA (42).
Similar to SAHA, ITF2357 (generic givi-
nostat) is a hydroxamic acid–containing
HDAC inhibitor that has antiinflamma-
tory properties in vitro and in vivo as
summarized in this issue of Molecular
Medicine. At therapeutic plasma levels of
125–250 nmol/L, there is no cell toxicity
in vitro, and only minor thrombocyto-
penia occurs in patients (43). Givinostat
has been administered for 12 weeks in
 children with systemic-onset juvenile
 idiopathic arthritis without side effects
at a therapeutically effective dose of
1.5 mg/kg (44). The use of HDAC in-
hibitors in rheumatoid arthritis is re-
viewed in the present issue (44). We have
examined the ability of ITF2357 to induce
HIV-1 gene expression in vitro from the
latently infected cell lines ACH2 (T-cell
line) and U1 (promoncytic line) (39).
Givinostat increased p24 by 15-fold in
ACH2 cells and, at clinically relevant con-
centrations, was approximately 10 times
more efficient in HIV-1 stimulation than
VPA. In U1 cells, VPA failed to double
HIV-1 expression, as measured by p24
levels, whereas 250 nmol/L of ITF2357
induced a nine-fold increase (39).
PXD101 (belinostat), another hydrox-
amic acid–containing HDAC inhibitor,
has activity against class I and II HDACs
at nanomolar concentrations, but is
slightly less potent than ITF2357 (45).
However, because PXD101 has primarily
been administered through the intra-
venous route for treatment of various
cancers (46), information on safety, toler-
ability and pharmacokinetics using oral
administration is still limited (47). Cer-
tainly, the side effects from the dosing
used in patients with refractory cancer
diseases will be unacceptable for 
HIV-1-infected patients on suppressive
HAART. As shown in Figure 2, we com-
pared the ability of VPA, SAHA, ITF2357
and PXD101 to induce HIV-1 expression
in the latently infected cell line U1.
ITF2357 and PXD101 stimulate HIV-1
 expression with a similar potency, and
both have activity within the low
125–500 nmol/L range. Higher concen-
trations of SAHA were needed to achieve
the same virus production, and, as ex-
pected, millimolar concentrations of VPA
were needed for HIV-1 expression in this
system (Figure 2).
THE IMPORTANCE OF HIV-1
SELECTIVITY
As reviewed above, class 1 HDACs
and specifically HDAC-1, -2 and -3 are
considered the major HDACs involved
in HIV-1 silencing. Therefore, the use of
selective HDAC inhibitors would be a
reasonable approach to increase its effi-
cacy and at the same time decrease any
adverse effects. Specific enzymatic activ-
ity assays have been used to compare the
selectivity of vorinostat, VPA and givino-
stat (39). Analogs of givinostat with a dif-
ferent selectivity profile were also exam-
ined. The class 1 HDAC selectivity pro-
file correlated directly with HIV-1 stimu-
lation from the latently infected U1 and
Ach2 cell lines. Whereas VPA showed a
weak and nonselective HDAC inhibition,
the most selective givinostat analog
showed a 30-fold increase in HIV-1 ex-
pression from ACH2 cells. This effect
was not due to cell stress. Interestingly, in
Ach2 cells, the degree of HDAC-2 inhibi-
tion was directly correlated with the in-
duction of HIV-1 gene expression (39).
These observations correlate well with
the molecular association between the
HIV-1 LTR and HDAC-1, -2 and -3.
A recent study by the Margolis group
demonstrated that HDAC inhibitors,
which specifically targeted class I
HDACs, induced HIV-1 gene expression
from cell lines as well as in resting CD4+
T cells of aviremic patients (48). An addi-
tive effect was seen with inhibition of
HDAC-6 as well. These findings support
data regarding the selectivity of class I
HDAC-1, -2 and -3 for induction of HIV-1
gene expression. However, preserving
the deacetylated status of HDAC-6 pre-
vents HIV-1 infected CD4+ T cells from
Env-mediated syncytia formation (49).
Therefore, analogs that have inhibitory
properties targeting HDAC-6 may not be
optimal.
EFFECT OF HDAC INHIBITION ON HIV-1
CORECEPTORS
Despite the fact that HDAC inhibitors
often increase gene expression, ITF2357
did not increase CCR5 surface expression
on CD4+ T cells (39). It would be counter-
productive if agents stimulating the latent
virus upregulated CCR5 and CXCR4 sur-
face expression. In fact, surface expression
of CXCR4 on CD4+ T cells and CCR5 on
monocytes was reduced by 50% by
ITF2357 (39). Consistent with decreasing
coreceptor surface expression, ITF2357 re-
duced steady-state mRNA levels of
CXCR4 and CCR5 in peripheral blood
mononuclear cells (PBMCs), as measured
by reverse transcriptase–polymerase chain
reaction (RT-PCR) and by Affimetrix gene
expression, respectively. Thus, in a clini-
Figure 2. HIV-1 expression in U1 cells stimu-
lated by ITF2357, PXD101, SAHA or VPA.
Mean ± SEM p24 levels of two separate
experiments for HDAC inhibitors (HDACi)
are indicated under the horizontal axis.
Phorbol-12-myristate-13-acetate (PMA) is
used as the positive control (omitted from
figure). ITF2357 was supplied by Italfar-
maco, SpA, Cinisello Balsamo, Italy; PXD101
and SAHA were purchased through
 Selleck Chemicals LLC (Houston, TX, USA).
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cal trial of givinostat in HIV-1-infected
patients, this property of givinostat may
also reduce any reinfection of naive CD4+
T cells.
STUDY DESIGN OF NEW HDAC
INHIBITORS IN HIV-1 PURGING
Safety is always a consideration when
evaluating a drug to treat a disease with
no immediate danger to the patient. In
testing the hypothesis that HDAC inhibi-
tion will purge the latent pool of HIV-1,
VPA falls short because of a low level of
induced expression compared with
ITF2357. Givostat is safe and effective in
humans. In healthy human subjects in a
phase I trial, a single dose of givinostat
of 1.5 mg/kg resulted in a peak plasma
level of 200 nmol/L (43). In a phase II
trial in children with active systemic-
onset juvenile idiopathic arthritis, a daily
oral dose of givinostat at 1.5 mg/kg for
12 weeks exhibited no organ toxicity and
achieved significant (P < 0.01) reduction
in parameters of systemic disease as well
as the number of painful joints (44). Doses
of VPA, on the other hand, when used to
reach concentrations >110 μg/mL in fe-
males or >135 μg/mL in males, carries
significant side effects and especially se-
vere thrombocytopenia (50). Thus, higher
concentrations of VPA would be imprac-
tical to induce more viral expression.
In light of the in vitro data suggesting
its potency in inducing HIV-1 expression
as well as the clinical data suggesting
that givinostat is safe, a phase II clinical
trial of givinostat would be worthwhile.
Administration of givinostat at 1.5 mg/kg
or possibly 1.0 mg/kg in two divided
doses may induce a limited number of
CD4+ T cells to express HIV-1. One end
point of such a study is whether after a
12-week course there is a reduction in
the inducible pool of latent virus. In ad-
dition, it would also be important to de-
termine whether anti–HIV-1 cytotoxic
T cells increased after these courses of
givinostat. Although some patients may
be reluctant to stop antiretroviral therapy
after courses of HDAC inhibitors, the ex
vivo testing of the reservoir would pro-
vide evidence that there has been an ob-
jective reduction in the latent pool.
Surely, the test of the hypothesis that
HDAC inhibitor can reduce the reservoir
comes with cessation of antiretroviral
therapy and the duration of time before
circulating mRNA levels reappear. Ide-
ally, there would be no return of viral
load. Nevertheless, a significant delay in
the return of viral load would provide
encouragement for the development of
specific targeting of HDACs that assist in
maintaining HIV-1 latency.
At another level, givinostat or a similar
well-tolerated HDAC inhibitor may pro-
vide an additional benefit to HIV-1-
infected patients. There are patients
being treated with antiretroviral therapy
with <50 copies of HIV-1 mRNA but who
succumb to all-cause mortality, particu-
larly cardiovascular and renal events
(51). In these patients, biomarkers of in-
flammation, C-reactive peptide (CRP),
IL-6 and D-dimer are elevated. The rela-
tive risk for death associated with ele-
vated CRP in these patients was 2.0: for
elevated IL-6, it was 8.3, and for D-dimer,
the increased risk was 12.4 (51). In pa-
tients who delay antiretroviral therapy,
there was an expected rise in CD4+ T cells
on initiation of antiretroviral therapy. Al-
though there was also a decrease in the
level of D-dimer, there was no change in
elevated IL-6 or CRP (52). It is presently
unclear whether the decrease in D-dimer
will reduce clinical disease; however, the
continued elevated IL-6 and CRP levels
indicate a continued inflammatory state,
even in patients being successfully
treated with antiretroviral therapy and
who sustain an increased risk for
non–HIV-1-associated death. Given the
antiinflammatory properties of HDAC
inhibitors, the markers of systemic in-
flammation may decrease in a study of
HIV-1 purging. On the other hand, it is
possible that markers of inflammation
may increase as a result of HIV-1 expres-
sion and inadequate prevention of rein-
fection by antiretroviral therapy.
CONCLUSION
Purging the latent reservoir of HIV-1
in resting CD4+ T cells by HDAC in-
hibitors is under active clinical investiga-
tion. Use of well-tolerated and selective
HDAC inhibitors for HIV-1 purging
should be tested in vitro and provide a
rationale for clinical studies in aviremic
HIV-1 patients on antiretroviral therapy.
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